Mer­ck part­ner Arti­va blue­prints San Diego R&D, man­u­fac­tur­ing site to take NK cell op­er­a­tion to the next lev­el

In Jan­u­ary, Arti­va Bio­ther­a­peu­tics CEO Fred Aslan said his com­pa­ny is look­ing to cre­ate CAR-NK ther­a­pies with best-in-class ef­fi­ca­cy made in a whol­ly owned man­u­fac­tur­ing process. Arti­va is now an­oth­er step clos­er to that goal.

Arti­va will open a 52,000 square-foot head­quar­ters in San Diego that will house its R&D and man­u­fac­tur­ing of NK cell ther­a­pies. The site will have a mul­ti-suite, cus­tom-built man­u­fac­tur­ing fa­cil­i­ty up to cur­rent GMP stan­dards and adds to its cur­rent man­u­fac­tur­ing op­er­a­tions at GC Lab­Cell’s 300,000-square-foot lo­ca­tion in South Ko­rea. This new site won’t re­place what’s go­ing on in Ko­rea but dou­ble down on the amount of ca­pac­i­ty the com­pa­ny has.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER